Oculis Holding AG is a global biopharmaceutical company developing innovative drug candidates to treat ophthalmic and neuro-ophthalmic diseases, with operations across multiple countries including Switzerland, Iceland, France, the United States, and Hong Kong. The company is in the late clinical-stage development phase and is not yet commercializing products; instead, it currently generates minimal revenue through government research and development grants while incurring substantial research and development expenses through collaborations with contract research organizations and clinical research sites. The company's long-term business model depends on successful regulatory approval and commercialization of its drug candidates, potential partnerships with pharmaceutical companies, and continued access to capital funding through equity offerings and credit facilities to advance its clinical programs toward regulatory submission.